Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Influenza

Free Subscription Articles published in J Gen Virol Retrieve available abstracts of 59 articles: HTML format

Single Articles

July 2023
1. THURSZ M, Sadiq F, Tree JA, Karayiannis P, et al
   Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.
   J Gen Virol. 2023;104.
   PubMed     Abstract available
   
   
   June 2023
2. OKUYA K, Khalil AM, Esaki M, Nishi N, et al
   Newly emerged genotypes of highly pathogenic H5N8 avian influenza viruses in Kagoshima prefecture, Japan during winter 2020/21.
   J Gen Virol. 2023;104.
   PubMed     Abstract available
   
   
   
3. MIRABELLI C, Bragazzi Cunha J, Wotring JW, Sherman EJ, et al
   ARF6 is a host factor for SARS-CoV-2 infection in vitro.
   J Gen Virol. 2023;104.
   PubMed     Abstract available
   
   
   
4. APAA T, Withers AJ, Staley C, Blanchard A, et al
   Sarbecoviruses of British horseshoe bats; sequence variation and epidemiology.
   J Gen Virol. 2023;104.
   PubMed     Abstract available
   
   
   May 2023
5. JAMES J, Billington E, Warren CJ, De Sliva D, et al
   Clade 2.3.4.4b H5N1 high pathogenicity avian influenza virus (HPAIV) from the 2021/22 epizootic is highly duck adapted and poorly adapted to chickens.
   J Gen Virol. 2023;104.
   PubMed     Abstract available
   
   
   
6. DE BUHR H, de Leeuw OS, Harders F, Peeters BP, et al
   Emergence of biased hypermutation in a heterologous additional transcription unit in recombinant lentogenic Newcastle disease virus.
   J Gen Virol. 2023;104.
   PubMed     Abstract available
   
   
   
7. SULLIVAN DJ, Franchini M, Senefeld JW, Joyner MJ, et al
   Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
   J Gen Virol. 2023;104.
   PubMed     Abstract available
   
   
   April 2023
8. SKOG E, Nykvist M, Naguib MM, Wille M, et al
   An oseltamivir-resistant avian H1N1 influenza A virus can transmit from mallards to chickens similarly to a wild-type strain: implications for the risk of resistance transmission to humans.
   J Gen Virol. 2023;104.
   PubMed     Abstract available
   
   
   
9. WOO PCY, de Groot RJ, Haagmans B, Lau SKP, et al
   ICTV Virus Taxonomy Profile: Coronaviridae 2023.
   J Gen Virol. 2023;104.
   PubMed     Abstract available
   
   
   February 2023
10. DANIELS RS, McCauley JW
    The health of influenza surveillance and pandemic preparedness in the wake of the COVID-19 pandemic.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    
11. PURVES K, Haverty R, O'Neill T, Folan D, et al
    A novel antiviral formulation containing caprylic acid inhibits SARS-CoV-2 infection of a human bronchial epithelial cell model.
    J Gen Virol. 2023;104.
    PubMed     Abstract available
    
    
    November 2022
12. ROY T, Sharma K, Dhall A, Patiyal S, et al
    In silico method for predicting infectious strains of influenza A virus from its genome and protein sequences.
    J Gen Virol. 2022;103.
    PubMed     Abstract available
    
    
    
13. GRAND RJ
    A link between severe hepatitis in children and adenovirus 41 and adeno-associated virus 2 infections.
    J Gen Virol. 2022;103.
    PubMed     Abstract available
    
    
    
14. DEMPSEY R, Ritter L, Parker L
    Strain development of A/H1N1pdm09 candidate vaccine viruses for the 2021-22 northern hemisphere influenza season.
    J Gen Virol. 2022;103.
    PubMed     Abstract available
    
    
    
15. JAMES J, Byrne AMP, Goharriz H, Golding M, et al
    Infectious droplet exposure is an inefficient route for SARS-CoV-2 infection in the ferret model.
    J Gen Virol. 2022;103.
    PubMed     Abstract available
    
    
    July 2022
16. SHARTOUNY JR, Lowen AC
    Message in a bottle: mRNA vaccination for influenza.
    J Gen Virol. 2022;103.
    PubMed     Abstract available
    
    
    June 2022
17. LIU L, Weiss A, Saul VV, Schermuly RT, et al
    Comparative kinase activity profiling of pathogenic influenza A viruses reveals new anti- and pro-viral protein kinases.
    J Gen Virol. 2022;103.
    PubMed     Abstract available
    
    
    May 2022
18. DE MOOR WRJ, Regnard GL, Rybicki EP, Williamson AL, et al
    Characterization of a dynamic self-replicating mammalian expression vector based on the circular ssDNA genome of beak and feather disease virus.
    J Gen Virol. 2022;103.
    PubMed     Abstract available
    
    
    April 2022
19. THAKUR N, Gallo G, Newman J, Peacock TP, et al
    SARS-CoV-2 variants of concern alpha, beta, gamma and delta have extended ACE2 receptor host ranges.
    J Gen Virol. 2022;103.
    PubMed     Abstract available
    
    
    March 2022
20. DOLINSKI AC, Homola JJ, Jankowski MD, Robinson JD, et al
    Differential gene expression reveals host factors for viral shedding variation in mallards (Anas platyrhynchos) infected with low-pathogenic avian influenza virus.
    J Gen Virol. 2022;103.
    PubMed     Abstract available
    
    
    November 2021
21. SEALY JE, Howard WA, Molesti E, Iqbal M, et al
    Amino acid substitutions in the H5N1 avian influenza haemagglutinin alter pH of fusion and receptor binding to promote a highly pathogenic phenotype in chickens.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
22. ORR-BURKS N, Murray J, Todd KV, Bakre A, et al
    MicroRNAs affect GPCR and Ion channel genes needed for influenza replication.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
23. VIANA K, Zarpelon L, Leandro A, Terencio M, et al
    Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
24. SZYMCZAK A, Jedruchniewicz N, Torelli A, Kaczmarzyk-Radka A, et al
    Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    October 2021
25. HUSSAIN S, Daniels RS, Wharton SA, Howell S, et al
    Reduced sialidase activity of influenza A(H3N2) neuraminidase associated with positively charged amino acid substitutions.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
26. MHAMDI Z, Carbonneau J, Venable MC, Baz M, et al
    Replication and transmission of an influenza A(H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
27. OLBRICH L, Castelletti N, Schalte Y, Gari M, et al
    Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    September 2021
28. STALLER E, Sheppard CM, Baillon L, Frise R, et al
    A natural variant in ANP32B impairs influenza virus replication in human cells.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    August 2021
29. HIRST JC, Hutchinson EC
    Corrigendum: Single-particle measurements of filamentous influenza virions reveal damage induced by freezing.
    J Gen Virol. 2021;102.
    PubMed    
    
    
    
30. RAHMAN F, Libre C, Oleinikov A, Tcherniuk S, et al
    Chloroquine and pyrimethamine inhibit the replication of human respiratory syncytial virus A.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    July 2021
31. POHL MO, Busnadiego I, Marrafino F, Wiedmer L, et al
    Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    June 2021
32. ELGENDY EM, Arai Y, Kawashita N, Isobe A, et al
    Double mutations in the H9N2 avian influenza virus PB2 gene act cooperatively to increase viral host adaptation and replication for human infections.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
33. CHAPPELL JG, Tsoleridis T, Clark G, Berry L, et al
    Retrospective screening of routine respiratory samples revealed undetected community transmission and missed intervention opportunities for SARS-CoV-2 in the United Kingdom.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    May 2021
34. DISSANAYAKE TK, Yan B, Ng AC, Zhao H, et al
    Differential role of sphingomyelin in influenza virus, rhinovirus and SARS-CoV-2 infection of Calu-3 cells.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
35. GOLDEN JW, Zeng X, Cline CR, Garrison AR, et al
    Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
36. ZHANG QY, Deng CL, Liu J, Li JQ, et al
    SARS-CoV-2 replicon for high-throughput antiviral screening.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    April 2021
37. HENSS L, Auste A, Schurmann C, Schmidt C, et al
    The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
38. SMITHER SJ, Eastaugh LS, Findlay JS, Laws TR, et al
    Investigative study into whether an insect repellent has virucidal activity against SARS-CoV-2.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
39. PEACOCK TP, Penrice-Randal R, Hiscox JA, Barclay WS, et al
    SARS-CoV-2 one year on: evidence for ongoing viral adaptation.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
40. DAVIES K, Buczkowski H, Welch SR, Green N, et al
    Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    March 2021
41. MONCHATRE-LEROY E, Lesellier S, Wasniewski M, Picard-Meyer E, et al
    Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
42. GUPTA A, Sabarinathan R, Bala P, Donipadi V, et al
    A comprehensive profile of genomic variations in the SARS-CoV-2 isolates from the state of Telangana, India.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
43. ROE MK, Junod NA, Young AR, Beachboard DC, et al
    Targeting novel structural and functional features of coronavirus protease nsp5 (3CL(pro), M(pro)) in the age of COVID-19.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
44. AUERSWALD H, Yann S, Dul S, In S, et al
    Assessment of inactivation procedures for SARS-CoV-2.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    
45. SIMMONDS P, Williams S, Harvala H
    Understanding the outcomes of COVID-19 - does the current model of an acute respiratory infection really fit?
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    February 2021
46. KHALIL AM, Yoshida R, Masatani T, Takada A, et al
    Variation in the HA antigenicity of A(H1N1)pdm09-related swine influenza viruses.
    J Gen Virol. 2021 Feb 22. doi: 10.1099/jgv.0.001569.
    PubMed     Abstract available
    
    
    
47. CLEMENTS AL, Peacock TP, Sealy JE, Lee HM, et al
    PA-X is an avian virulence factor in H9N2 avian influenza virus.
    J Gen Virol. 2021 Feb 5. doi: 10.1099/jgv.0.001531.
    PubMed     Abstract available
    
    
    January 2021
48. KIM DI, Cho YB, Lim Y, Hong SH, et al
    Chios mastic gum inhibits influenza A virus replication and viral pathogenicity.
    J Gen Virol. 2021 Jan 8. doi: 10.1099/jgv.0.001550.
    PubMed     Abstract available
    
    
    
49. THAKUR N, Conceicao C, Isaacs A, Human S, et al
    Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell-cell fusion.
    J Gen Virol. 2021;102.
    PubMed     Abstract available
    
    
    December 2020
50. HARRIS M
    Microbiology Society online workshop on SARS-CoV-2 and COVID-19, Wednesday 29 July 2020.
    J Gen Virol. 2020;101:1227-1228.
    PubMed    
    
    
    November 2020
51. YU J, Li F, Wang D
    The first decade of research advances in influenza D virus.
    J Gen Virol. 2020 Nov 19. doi: 10.1099/jgv.0.001529.
    PubMed     Abstract available
    
    
    
52. KLIMSTRA WB, Tilston-Lunel NL, Nambulli S, Boslett J, et al
    SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients.
    J Gen Virol. 2020;101:1156-1169.
    PubMed     Abstract available
    
    
    October 2020
53. LI Y, Chai W, Min J, Ye Z, et al
    Neddylation of M1 negatively regulates the replication of influenza A virus.
    J Gen Virol. 2020 Oct 5. doi: 10.1099/jgv.0.001503.
    PubMed     Abstract available
    
    
    
54. FIRTH AE
    A putative new SARS-CoV protein, 3c, encoded in an ORF overlapping ORF3a.
    J Gen Virol. 2020;101:1085-1089.
    PubMed     Abstract available
    
    
    
55. SILVA SJRD, Germano Mendes RP, Alves da Silva CT, Lorusso A, et al
    Insights into SARS-CoV-2, the Coronavirus Underlying COVID-19: Recent Genomic Data and the Development of Reverse Genetics Systems.
    J Gen Virol. 2020;101:1021-1024.
    PubMed     Abstract available
    
    
    
56. RENNICK LJ, Nambulli S, Lemon K, Olinger GY, et al
    Recombinant subtype A and B human respiratory syncytial virus clinical isolates co-infect the respiratory tract of cotton rats.
    J Gen Virol. 2020;101:1056-1068.
    PubMed     Abstract available
    
    
    
57. RIJSBERGEN LC, Rennick LJ, Laksono BM, van Run PRWA, et al
    In vivo comparison of a laboratory-adapted and clinical-isolate-based recombinant human respiratory syncytial virus.
    J Gen Virol. 2020;101:1037-1046.
    PubMed     Abstract available
    
    
    September 2020
58. MOOIJ P, Mortier D, Stammes M, Fagrouch Z, et al
    Aerosolized pH1N1 influenza infection induces less systemic and local immune activation in the lung than combined intrabronchial, nasal and oral exposure in cynomolgus macaques.
    J Gen Virol. 2020 Sep 25. doi: 10.1099/jgv.0.001489.
    PubMed     Abstract available
    
    
    
59. WANG J, Xu X, Zhou X, Chen P, et al
    Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection.
    J Gen Virol. 2020;101:921-924.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: